Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Disease Clear all
Terminated Not applicable Interventional

A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement

NCT01644526
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Hemoaccess Valve System
Device
Lead sponsor
Diaxamed LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis

NCT00939952
View directory record Official record
Conditions
Continuous Ambulatory Peritoneal Dialysis, End Stage Renal Disease
Interventions
ertapenem
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Clifton Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

NCT03771963
View directory record Official record
Conditions
Dengue Fever
Interventions
Tetravalent Dengue Vaccine (TDV)
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Anaheim, California • Hutchinson, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Phase 2 Interventional Results available

Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients

NCT00240994
View directory record Official record
Conditions
Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions
Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 23, 2026, 3:15 PM EDT
Active, not recruiting Not applicable Interventional

Trial to Evaluate and Assess the Effect of Comprehensive Pre-ESKD Education on Home Dialysis Use in Veterans

NCT04064086
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Hemodialysis, Peritoneal Dialysis
Interventions
Comprehensive Pre-ESRD Patient Education (CPE), Provision of the freely available resources for Kidney Disease Education
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 3:15 PM EDT
Completed No phase listed Observational Results available

Comparing Ankle Fusion to Ankle Replacement

NCT01620541
View directory record Official record
Conditions
End-stage Ankle Arthritis (ESAA), Osteoarthritis (OA)
Interventions
Ankle Arthrodesis, Ankle Arthroplasty
Procedure
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
21 Years to 89 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
6
States / cities
Fort Collins, Colorado • Grand Rapids, Michigan • Edina, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 3:15 PM EDT
Recruiting No phase listed Observational

Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

NCT05880537
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Nexeon Arterial Venous Allograft
Other
Lead sponsor
LifeNet Health
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Mobile, Alabama • Sylmar, California • Torrance, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 3:15 PM EDT
Recruiting Phase 1 Interventional

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

NCT06056102
View directory record Official record
Conditions
Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
Interventions
Cyclophosphamide, CART-BCMA, huCART19
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Not applicable Interventional Results available

Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis

NCT04985383
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
AKST1210 S-15 at 250 mL/min, AKST1210 S-15 at 450 mL/min, AKST1210 S-25 at 250 mL/min, AKST1210 S-25 at 450 mL/min, AKST1210 S-35 at 250 mL/min, AKST1210 S-35 at 450 mL/min
Device
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Granada Hills, California • Northridge, California • Gallup, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 23, 2026, 3:15 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

NCT04678505
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-3402
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis

NCT04622709
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Furosemide (loop diuretic) Tablets
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Carrboro, North Carolina • Pittsboro, North Carolina • Sanford, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Not applicable Interventional Results available

Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap

NCT02593149
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
ClearGuard HD End Cap
Device
Lead sponsor
Pursuit Vascular, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 23, 2026, 3:15 PM EDT
Completed No phase listed Observational

Events Before Death

NCT01329055
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 88 Years
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Not applicable Interventional Results available

Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?

NCT02526680
View directory record Official record
Conditions
Glaucoma
Interventions
OrCam
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 23, 2026, 3:15 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

NCT01922999
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease, Sleep Disorder
Interventions
Melatonin
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Not applicable Interventional Results available

The EvAluation of TaBlo In-CLinic and In-HOme

NCT02460263
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tablo Hemodialysis System
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 23, 2026, 3:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Sit Less, Interact, Move More (SLIMM) Regimen on Patients With Chronic Kidney Disease (CKD)

NCT02924298
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease
Interventions
SLIMM
Behavioral
Lead sponsor
Srinvasan Beddhu
Other
Eligibility
18 Years to 95 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 23, 2026, 3:15 PM EDT
Active, not recruiting No phase listed Observational

Outcome of BCF Access in Hemodialysis Patients

NCT01693263
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Brachiocephalic Fistula (BCF), Cephalic Arch Stenosis (CAS), Dialysis
Interventions
brachiocephalic fistula (BCF)
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 23, 2026, 3:15 PM EDT
Terminated Phase 2 Interventional

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

NCT00228592
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepeX-B, Hepatitis B Immune Globulin (HBIg)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 23, 2026, 3:15 PM EDT
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
View directory record Official record
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 3:15 PM EDT
Terminated Not applicable Interventional Results available

Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients

NCT00604565
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
soluble ferric pyrophosphate (SFP), placebo
Drug · Other
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Phase 4 Interventional Results available

Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

NCT03627299
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
300mg glecaprevir/pibrentasivir 120mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 23, 2026, 3:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

NCT02729038
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 23, 2026, 3:15 PM EDT